Literature DB >> 15381632

Proteinase-activated receptor pharmacology: trickier and trickier.

James D Moffatt1.   

Abstract

Proteinase-activated receptors (PARs) are G-protein-coupled receptors for serine and other proteinases. Peptide agonists of these receptors are frequently used to characterise the presence and role of PARs in cells and organ systems. However, the specificity of these peptides is questionable in some assay systems. In this issue, Hollenberg et al. report very different effects of PAR(4) receptors in various assays. Their results suggest the existence of unknown receptors and further highlight the need to use peptide PAR agonists with due caution.

Mesh:

Substances:

Year:  2004        PMID: 15381632      PMCID: PMC1575415          DOI: 10.1038/sj.bjp.0705949

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  4 in total

Review 1.  International Union of Pharmacology. XXVIII. Proteinase-activated receptors.

Authors:  Morley D Hollenberg; Steven J Compton
Journal:  Pharmacol Rev       Date:  2002-06       Impact factor: 25.468

2.  Endothelium-dependent contractile actions of proteinase-activated receptor-2-activating peptides in human umbilical vein: release of a contracting factor via a novel receptor.

Authors:  M Saifeddine; S S Roy; B Al-Ani; C R Triggle; M D Hollenberg
Journal:  Br J Pharmacol       Date:  1998-12       Impact factor: 8.739

Review 3.  Shooting for PARs in lung diseases.

Authors:  James D Moffatt; Clive P Page; Geoffrey J Laurent
Journal:  Curr Opin Pharmacol       Date:  2004-06       Impact factor: 5.547

4.  Proteinase-activated receptor (PAR)-1 and -2 agonists induce mediator release from mast cells by pathways distinct from PAR-1 and PAR-2.

Authors:  Grant R Stenton; Osamu Nohara; René E Déry; Harissios Vliagoftis; Mark Gilchrist; Ankur Johri; John L Wallace; Morley D Hollenberg; Redwan Moqbel; A Dean Befus
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

  4 in total
  2 in total

Review 1.  TRPV4 as a therapeutic target for joint diseases.

Authors:  Amy L McNulty; Holly A Leddy; Wolfgang Liedtke; Farshid Guilak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-12-18       Impact factor: 3.000

Review 2.  The emergence of proteinase-activated receptor-2 as a novel target for the treatment of inflammation-related CNS disorders.

Authors:  Trevor Bushell
Journal:  J Physiol       Date:  2007-03-08       Impact factor: 5.182

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.